Stock Performance and Market Context
On 20 Feb 2026, Mankind Pharma Ltd’s stock price fell to Rs.2016, the lowest level in the past year. This decline comes after two consecutive days of losses, during which the stock has delivered a cumulative return of -2.47%. The day’s performance saw the stock underperform the Pharmaceuticals & Biotechnology sector by -0.85%, continuing a trend of relative weakness.
The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum. This contrasts with the broader market, where the Sensex rebounded sharply after an initial negative opening, closing at 82,814.71 points, up 0.38% for the day. The Sensex remains within 4.04% of its 52-week high of 86,159.02, supported by gains in mega-cap stocks.
Comparative Returns and Historical Performance
Over the past year, Mankind Pharma Ltd has delivered a negative return of -13.87%, significantly lagging the Sensex’s positive 9.35% gain over the same period. The stock’s 52-week high was Rs.2726.75, indicating a substantial decline of approximately 26% from that peak. This underperformance extends beyond the last year, with the stock trailing the BSE500 index over the last three years, one year, and three months, highlighting a persistent trend of below-par returns.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
Financial Metrics and Valuation Concerns
Mankind Pharma Ltd’s recent financial results have been largely flat, with profits declining by -8.1% over the past year. The company’s return on capital employed (ROCE) for the half-year period stands at 11.7%, which is considered low relative to its historical performance and industry peers. This is further reflected in the company’s enterprise value to capital employed ratio of 4.4, indicating a relatively expensive valuation.
Additional financial ratios highlight areas of concern. The ROCE for the half-year is reported at 12.33%, the lowest in recent periods, while the debtors turnover ratio has declined to 7.13 times, signalling slower collection efficiency. These metrics contribute to the stock’s downgrade from a Hold to a Sell rating on 19 Nov 2025, with a current Mojo Score of 38.0 and a Mojo Grade of Sell. The market capitalisation grade remains low at 2, reflecting the company’s modest size relative to its valuation.
Operational and Market Positioning Factors
Despite the challenges reflected in valuation and returns, Mankind Pharma Ltd maintains certain strengths. The company exhibits high management efficiency, with a reported ROCE of 25.78% in other periods, indicating effective capital utilisation in some segments. Its debt servicing capability is robust, with a low Debt to EBITDA ratio of 0.54 times, suggesting manageable leverage levels.
Long-term growth metrics remain healthy, with net sales growing at an annual rate of 18.21% and operating profit increasing at 18.72%. These figures demonstrate the company’s ability to expand its top and bottom lines over time, despite recent profit pressures.
Institutional investors hold a significant stake of 24.59%, reflecting confidence from entities with extensive resources and analytical capabilities. This level of institutional ownership often provides a degree of stability in shareholding patterns.
Why settle for Mankind Pharma Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology mid-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary of Key Indicators
Mankind Pharma Ltd’s stock performance and financial indicators present a mixed picture. The stock’s fall to Rs.2016 marks a significant technical low, underscored by underperformance relative to the Sensex and its sector. The downgrade to a Sell rating and a Mojo Score of 38.0 reflect concerns over valuation and recent profit trends.
However, the company’s strong management efficiency, healthy sales growth, and low leverage provide a foundation of operational strength. Institutional ownership remains substantial, indicating continued interest from sophisticated investors.
Overall, the stock’s current position at a 52-week low highlights the challenges faced in recent periods, with valuation and profitability metrics weighing on market sentiment.
Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today
